GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
![GlobeNewswire](../../../Content/images/providers/GN.png)
GRI Bio, Inc. (GRI)
Company Research
Source: GlobeNewswire
Data presented at the 14th International Congress on Autoimmunity Encouraging preclinical data observed to date on par with OFEV® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion1 Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024 LA JOLLA, CA, May 21, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio presented encouraging preclinical data from the Company’s preclinical studies of type 2 NKT activating molecules, GRI-0803 and GRI-0124 at the 14th International Congress on Autoimmunity held May 17-20, 2024 in Ljubljana, Slovenia (the Congress). GRI Bio’s second asset in development, GRI-0803, is a
Show less
Read more
Impact Snapshot
Event Time:
GRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRI alerts
High impacting GRI Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRI
News
- GRI Bio Announces Reverse Stock SplitGlobeNewswire
- GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference [Yahoo! Finance]Yahoo! Finance
- GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch ConferenceGlobeNewswire
- GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs [Yahoo! Finance]Yahoo! Finance
- GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) ProgramsGlobeNewswire
GRI
Sec Filings
- 6/26/24 - Form S-1/A
- 6/26/24 - Form S-1/A
- 6/20/24 - Form S-1
- GRI's page on the SEC website